When Sequenom releases its second-quarter earnings Thursday morning, investors, customers, and collaborators will be looking to see whether the company can arrest a six-month slide in its stock price.
Though quarterly revenues have grown since the second period last year, receipts for the first three months of 2004 have fallen by $2.3 million year over year because of a challenging market for high-throughput genotyping systems.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.